why am i not losing weight on compounded semaglutide compound Semaglutide Weight Loss Injection In St. Louis not losing weight on semaglutide

Administration: Tirzepatide should be administered once weekly via subcutaneous injection at consistent times

When GLP-1 receptors in the gut are activated whether by endogenous hormone or by a receptor agonist drug several physiological changes occur

Retatrutide versus other weight loss peptides Compared to semaglutide: Semaglutide targets only GLP-1 receptors, achieving approximately 15-17% weight loss in clinical trials

Mackie, A

Strategies for maintaining results Three approaches can help preserve the benefits achieved during retatrutide treatment

Extended slow titration (for sensitive individuals) Some researchers have heightened sensitivity to GLP-1 receptor activation